Endometrial Cancer (see Uterine Cancer, [[Uterine Cancer]])
Breast Cancer (see Breast Cancer, [[Breast Cancer]])
Neuroendocrine Tumors
Advanced Renal Cell Carcinoma (see Renal Cancer, [[Renal Cancer]])
Pharmacology
Mechanistic Target of Rapamycin (mTOR) Inhibitor (see Mechanistic Target of Rapamycin Inhibitors, [[Mechanistic Target of Rapamycin Inhibitors]]): immunosuppressive and antiproliferative
Administration
xxxx
Adverse Effects
Pulmonary Adverse Effects
General Comments
36% of cases develop pulmonary toxicity, only half of which are symptomatic